Nancy A. Melville is a journalist who specializes in medical and healthcare topics. She writes for several publications, including Medscape, MDEdge, and Knowledia. Nancy's articles cover a wide range of subjects, including weight loss, diabetes care, cancer treatments, and the impact of stress on health.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nancy's articles predominantly focus on healthcare and scientific themes, especially in areas related to leukemia, cancer treatment, and pharmaceuticals. She often cites data to support her findings and includes expert commentary.
For effective outreach, consider providing Nancy with access to new research or data-driven insights into the topics she covers. Medical professionals with expertise in leukemia treatments, cancer research specialists, or pharmaceutical industry experts may be valuable sources for her articles.
Since Nancy does not have a specific geographic focus mentioned, relevant information from across the globe would likely interest her if it aligns with her coverage areas.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.
By: Nancy A. Melville
SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy
Pegcetacoplan substantially reduced proteinuria in these potentially debilitating rare kidney diseases in a new phase 3 study.
By: Nancy A. Melville
SAN DIEGO — The use of a targeted plasma sodium correction did not reduce 30-day mortality and rehospitalization rates in hospitalized patients with
SAN DIEGO – Patients receiving cancer treatment, while having an increased risk for acute kidney injury (AKI) linked to various cancer treatment
A preliminary study showed first evidence of normalization of T3, T4, within weeks, with additional thyroid eye disease effects.
Pembrolizumab Boosts Survival in Anaplastic Thyroid Cancer
The first pregnancy guideline updates from the American Thyroid Association since 2017 to emphasize shared decision-making, key treatment/testing recommendation changes.
CHICAGO — A preview of much-anticipated updates to guidelines on managing thyroid disease in pregnancy shows key changes to recommendations in the evolving field, ranging from consideration of the chance of spontaneous normalization of thyroid levels during pregnancy to a heightened emphasis on shared decision-making and the nuances can factor into personalized treatment.
Poorly controlled blood pressure among key risk factors in rare but potentially lethal neck hematomas occurring after thyroidectomy.
(833) 317-6278 
